Targets of Acinetobacter Baumannii
Inventors
Urwyler, Simon • Haake, Markus • Rudolf, Michael
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
Core Innovation
The described invention provides an immunogenic composition comprising isolated antigenic polypeptides for generating an immune response against Acinetobacter baumannii in a subject in need thereof. The compositions include an isolated polypeptide encoded by a recombinant nucleic acid with a specified polynucleotide sequence (SEQ ID NO: 1) and an immuno-effective amount of an adjuvant. The antigenic polypeptides are described as immunostimulatory and are intended to induce antibody responses against A. baumannii.
The invention further defines recombinant antigenic polypeptides by amino acid sequence, including an immunostimulatory recombinant antigenic polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 in combination with an immuno-effective amount of an adjuvant. Additional embodiments include a composition comprising the isolated recombinant polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 together with a His tag, and an effective amount of an adjuvant.
The disclosure also describes antibody concepts and antigen target selection tied to conservation and clinical prevalence across A. baumannii isolates. Antibodies and binding epitopes are described, including an epitope consensus motif PVDFTVAI (SEQ ID NO: 36). Immunogenicity and prevalence are supported by detection and binding assays with patient serum and convalescent antibody detection, together with binding specificity approaches and the stated presence of the targets in clinical isolates.
Claims Coverage
The partial independent claims cover three inventive compositions centered on recombinant antigenic polypeptides defined by SEQ ID NO: 1 or SEQ ID NO: 2, each combined with an immuno-effective/effective amount of an adjuvant, with one embodiment additionally requiring a His tag and one embodiment optionally adding a delivery vehicle.
Recombinant polypeptide encoded by SEQ ID NO: 1 with adjuvant
An immunogenic composition comprising an isolated polypeptide encoded by a recombinant nucleic acid molecule consisting of the polynucleotide sequence of SEQ ID NO: 1, and an immuno-effective amount of an adjuvant, wherein the composition is effective in generating an immune response against Acinetobacter baumannii in a subject in need thereof.
Recombinant antigenic polypeptide with immunostimulatory activity using SEQ ID NO: 2
An immunogenic composition comprising an isolated recombinant antigenic polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 having immunostimulatory activity in combination with an immuno-effective amount of an adjuvant.
Recombinant polypeptide of SEQ ID NO: 2 with His tag and adjuvant
A composition comprising an isolated recombinant polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 and a His tag, and the composition comprising an effective amount of an adjuvant.
Across the independent claims, the core coverage is the combination of specifically defined recombinant A. baumannii antigenic polypeptides (SEQ ID NO: 1 or SEQ ID NO: 2) with an immuno-effective/effective amount of an adjuvant to generate an immune response; one independent claim further requires a His tag on the SEQ ID NO: 2 polypeptide.
Stated Advantages
Effective in generating an immune response against Acinetobacter baumannii in a subject in need thereof.
Documented Applications
Inducing antibody responses against Acinetobacter baumannii, including antibody detection and binding specificity analyses described using patient serum and convalescent antibodies.
Immunogenicity and functional protection are described using active and passive immunization in mouse pneumonia models.
Use of compositions for generating an immune response against Acinetobacter baumannii in a subject in need thereof.
Interested in licensing this patent?